Oruka Therapeutics’ (ORKA) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note published on Monday,Benzinga reports. BTIG Research currently has a $56.00 target price on the stock.

Several other equities analysts have also recently issued reports on ORKA. Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 18th. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Buy” and an average target price of $42.00.

Oruka Therapeutics Stock Up 26.9%

Shares of NASDAQ:ORKA opened at $19.29 on Monday. The firm has a 50-day simple moving average of $15.01 and a 200 day simple moving average of $12.44. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The company has a market cap of $722.41 million, a PE ratio of -6.86 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. As a group, research analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the period. Legal & General Group Plc purchased a new stake in Oruka Therapeutics during the second quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics in the second quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Oruka Therapeutics in the second quarter worth about $68,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Oruka Therapeutics in the second quarter worth approximately $96,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.